To evaluate the efficacy and toxicity of ACTIVE induction treatment followed by maintenance low dose cytarabine (LDAraC) + Venetoclax and DLI for post-alloSCT relapsed AML patients
Latest Information Update: 24 Jan 2022
Price :
$35 *
At a glance
- Drugs Venetoclax (Primary) ; Cytarabine; Dactinomycin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 21 Jul 2020 New trial record
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association